Angelini Pharma, an international pharmaceutical company which is a part of the private Italian Angelini Group, and Arvelle Therapeutics, a Swiss-based biopharma focused on central nervous system (CNS) disorders, have concluded a definitive merger agreement under which Angelini Pharma will acquire Arvelle Therapeutics for up to $960 million. Following regulatory approval, $610 million will be paid. Subsequently, and subject to cenobamate reaching certain revenue targets, a further $350 million w...